- Home
- HRMY vs TDC Comparison
HRMY vs TDC Comparison
Compare HRMY & TDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- TDC
- Stock Information
- Founded
- HRMY 2017
- TDC 1979
- Country
- HRMY United States
- TDC United States
- Employees
- HRMY N/A
- TDC N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- TDC Computer Software: Prepackaged Software
- Sector
- HRMY Health Care
- TDC Technology
- Exchange
- HRMY Nasdaq
- TDC Nasdaq
- Market Cap
- HRMY 1.9B
- TDC 1.9B
- IPO Year
- HRMY 2020
- TDC 2007
- Fundamental
- Price
- HRMY $26.11
- TDC $20.95
- Analyst Decision
- HRMY Strong Buy
- TDC Buy
- Analyst Count
- HRMY 10
- TDC 7
- Target Price
- HRMY $50.80
- TDC $29.67
- AVG Volume (30 Days)
- HRMY 1.0M
- TDC 1.2M
- Earning Date
- HRMY 10-28-2025
- TDC 11-04-2025
- Dividend Yield
- HRMY N/A
- TDC N/A
- EPS Growth
- HRMY 58.41
- TDC 79.70
- EPS
- HRMY 3.10
- TDC 1.13
- Revenue
- HRMY $772,527,000.00
- TDC $1,675,000,000.00
- Revenue This Year
- HRMY $19.94
- TDC N/A
- Revenue Next Year
- HRMY $16.65
- TDC N/A
- P/E Ratio
- HRMY $8.37
- TDC $18.37
- Revenue Growth
- HRMY 17.74
- TDC N/A
- 52 Week Low
- HRMY $25.58
- TDC $18.43
- 52 Week High
- HRMY $41.61
- TDC $33.69
- Technical
- Relative Strength Index (RSI)
- HRMY 30.89
- TDC 45.86
- Support Level
- HRMY $25.95
- TDC $20.63
- Resistance Level
- HRMY $26.97
- TDC $21.56
- Average True Range (ATR)
- HRMY 0.79
- TDC 0.80
- MACD
- HRMY 0.19
- TDC -0.13
- Stochastic Oscillator
- HRMY 26.11
- TDC 22.81
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.